More Videos
SPECIAL REPORT
MOST SHARED
- Warren Buffett and Bill Gates Share Their 'Optimism' With Eager Columbia Business Students
- Pharma & Social Media
- Cities With the Most Home Price Reductions
- Warren Buffett's $100,000 Offer and $500,000 Advice for Columbia Business School Students
- Disney Profit, Sales Top Street Forecasts; Shares Jump
- Is Euphoric Market Ignoring Warning Signs?
- Housing Recovery 'Still In Uncharted Territory': HUD Secretary
- Despite Rhetoric, Obama Has Limited Options To Boost Jobs
- Disney CFO and Parks Chief to Swap Roles
- Microsoft's Bill Gates Praises Apple's Steve Jobs For 'Saving the Company'
- Gold Is a Bad Inflation Hedge—Like Oil: Stock Picker
- Intel's Andy Bryant Offers An Explanation
- US 'Actively Working' on Weaker Dollar: Fund Manager
- Options Boil on Biotech Buyout Rumors
- Warren Buffett's $100,000 Offer and $500,000 Advice for Columbia Business School Students
- Activision Blizzard's "Modern Warfare 2" Sales Break Records
- 5-Star Manager's 5 Stocks for Changing Markets
- What's The Forecast from Retailers? Proceed With Caution
- Job Market Politics to Keep Interest Rates Low
- AIG, Symbol of Crisis, Watches Its Stock Zoom Back
- Disney Profit, Sales Top Street Forecasts; Shares Jump
- Bill Gates Praises Apple's Jobs for 'Saving the Company'
- Cities With the Most Home Price Reductions
- Cramer: The Real Reason Stocks Fell Thursday
- Is Euphoric Market Ignoring Warning Signs?
- Video Game Sales Plunge, but Have They Hit Bottom?
- Despite Rhetoric, Obama Has Few Options to Boost Jobs
RSS FEED
Pharma's Market
Text Size 
 |
AP |
](data) and ImClone Systems [IMCL
Loading...
()
](a deal). And the folks at Datamonitor, a business intelligence/research outfit that covers a bunch of sectors including drugs and healthcare, say we could see more ImClone-style deals. Before I get to that, Bristol-Myers Squibb[BMY
Loading...
()
] put out a press release saying, as an IMCL stakeholder, the company stands to pocket $1 billion in the Eli Lilly-ImClone deal and that it decided it was in the best interest of BMY shareholders not to offer more than $62 a share for IMCL.
Datamonitor is out with a piece today titled, "Opportunity Knocks for Big Pharma in Credit Crunch." The author points out that the "average net debt as a proportion of capital employed for the top 20 pharmaceutical companies is just 6 percent, while the average net debt carried by financial institutions is 95 percent. This fact alone suggests that the fallout from the credit crisis will not be as significant as in other more highly leveraged sectors."
In the current environment, Datamonitor argues that cash-strapped biotechs are losing leverage and that big pharma's "bargaining power and acquisitive tendencies will blossom in the credit crunch." The report says that the average top 20 pharma company is sitting on $7.5 billion in cash or stuff it can quickly turn into cash. "Pharma's cash pile means that it is now the only serious 'buyer in the room'--private equity has vanished and small players will lose their own sources of funding," Datamonitor writes.
Indeed, LLY [LLY
Loading...
()
]is doing its $6.5 billion deal with IMCL with no financing required. The report singles out Pfizer[PFE
Loading...
()
]. though, which is estimated to have more than $25 billion in cash and short-term investments. That cash hoarde dwarfs the amount held by the next-closest competitors including Novartis[NVS
Loading...
()
], Roche and Wyeth[WYE
Loading...
()
], in that descending order.
"It may well be that the credit crunch provides Big Pharma with exactly the opportunity it needs to rebuild its ailing pipelines," Datamonitor concludes. For now, at least, the market isn't buying into the theory. All of the usual-suspect biotech takeout targets are getting hammered. Then there's ImClone and Dendreon, which is one of only three Nasdaq stocks to hit a new high today.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes